"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02465099","Posterior Spinal Fusion With Two Energy Dissection Techniques",,"Terminated","Has Results","Scoliosis","Device: Ultrasonic Dissection (UD)|Device: Electrocautery Dissection (ED)","Estimated Intraoperative Blood Loss","Ethicon Endo-Surgery|Children's Hospital Medical Center, Cincinnati","All","10 Years to 21 Years   (Child, Adult)","Phase 4","64","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENG 14-004","June 1, 2015","May 1, 2016","May 1, 2016","June 8, 2015","February 19, 2018","February 19, 2018","Valley Children's Hospital, Madera, California, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Shriners Hospital for Children - Chicago, Chicago, Illinois, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Shriners Hospitals for Children-Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02465099"
2,"NCT02502526","Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses",,"Completed","Has Results","Cataracts","Device: Centurion® Vision System, 45° Balanced Tip|Device: Centurion® Vision System, 45° MFK Tip|Device: lnfiniti® Vision System, 45° MFK Tip|Device: INTREPID® Ultra infusion sleeve|Device: Ultra infusion sleeve","Cumulative Dissipated Energy (CDE)|Balanced Salt Solution (BSS) Fluid Used","Alcon Research","All","21 Years and older   (Adult, Older Adult)","Not Applicable","231","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CTU424-P001","July 27, 2015","March 23, 2017","November 30, 2017","July 20, 2015","April 18, 2018","July 2, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02502526/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02502526/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02502526"
3,"NCT01998737","Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX",,"Completed","Has Results","Osteoporosis",,"Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis|Specificity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis|Number of Participants That Would Require Additional DXA Examination to Confirm Diagnosis","Bone Index Finland Ltd|Merck Sharp & Dohme Corp.","Female","50 Years to 79 Years   (Adult, Older Adult)",,"1011","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Bind03|BoneIndex03","November 2013","March 2016","March 2016","December 2, 2013","August 11, 2017","September 21, 2017","Terveystalo Kamppi, Helsinki, Finland|Terveystalo Jyväskylä, Jyväskylä, Finland|Terveystalo Kouvola, Kouvola, Finland|Kuopio University Hospital, Kuopio, Finland|Terveystalo Lahti, Lahti, Finland|Terveystalo Mikkeli Marski, Mikkeli, Finland",,"https://ClinicalTrials.gov/show/NCT01998737"
4,"NCT02917642","Effect of Passive Ultrasonic Irrigation on the Reduction of Bacteria and Endotoxins in Root Canals",,"Completed","Has Results","Tooth, Nonvital","Device: Ultrasonic Irrigation|Device: Non-Ultrasonic Irrigation","Bacterial Levels|Endotoxin Levels","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FAPESP2013/02923-9","January 2014","July 2016","December 2016","September 28, 2016","July 3, 2018","July 3, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02917642/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02917642"
5,"NCT03351335","Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients","ULT-302","Completed","Has Results","Mild to Moderate Skin Laxity Under the Chin|Mild to Moderate Skin Laxity on Neck","Device: Microfocused ultrasound with visualization","Mean Change From Baseline in Overall Lifting and Tightening of Submental (Under the Chin) and Neck Tissue Area at Day 90 Post-treatment|Number of Participants With Improvement From Baseline in Overall Lifting and Tightening of Submental (Under the Chin) and Neck Tissue Area as Assessed by Physician Global Aesthetic Improvement Scale (PGAIS) Scores at Day 90 Post-treatment|Number of Participants With Improvement From Baseline in Overall Lifting and Tightening of Submental (Under the Chin) and Neck Tissue Area as Assessed by Subject Global Aesthetic Improvement Scale (SGAIS) at Day 90 Post-treatment|Number of Participants With Improvement From Baseline in Overall Lifting and Tightening of Submental (Under the Chin) and Neck Tissue Area as Assessed by a Masked, Qualitative Assessment of Photographs at Day 90 Post-treatment|Number of Participants With Satisfaction Responses as Assessed by Patient Satisfaction Questionnaire (PSQ) at Day 90 Post-treatment","Merz North America, Inc.|Ulthera, Inc","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M960001052","August 10, 2017","August 9, 2018","August 9, 2018","November 22, 2017","August 28, 2019","August 28, 2019","Merz Investigational Site # 0010411, Los Gatos, California, United States|Merz Investigational Site # 0010321, San Diego, California, United States|Merz Investigational Site # 0010358, Vista, California, United States|Merz Investigational Site # 0010410, Austin, Texas, United States|Merz Investigational Site # 0010422, Bellaire, Texas, United States|Merz Investigational Site # 0010423, Houston, Texas, United States|Merz Investigational Site # 0010125, Plano, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03351335/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03351335/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03351335"
6,"NCT04633642","Ultrasound Assisted Wound Debridement (UAW) Versus Standard Wound Treatment in Complicated Diabetic Foot Ulcers (DFU)",,"Completed","Has Results","Diabetic Foot Ulcer","Procedure: Ultrasound group|Procedure: Surgical group","Change From Baseline Neo-angiogenesis (Microvessel Density) at 6 Weeks|Change From Baseline Collagen Formation (Collagen Content ) at 6 Weeks|Change From Baseline Myofibroblasts Formation (Myofibroblasts Content) at 6 Weeks|Comparison of Quantitative Microbiological Analysis (Bacterial Counts Expressed Colony-forming Units Per Gram of Tissue) (CFU/g)|Wound Score at 6 Weeks|Wound Size","Universidad Complutense de Madrid|Francisco Javier Álvaro Afonso|David Sevillano Fernández|Yolanda García Álvarez|Irene Sanz Corbalan|Esther García Morales","All","18 Years and older   (Adult, Older Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","C.P. - C.I. 16/484-P","November 1, 2017","November 1, 2018","December 31, 2019","November 18, 2020","July 14, 2021","July 14, 2021","Fancisco Javier Álvaro Afonso, Madrid, Spain|José Luis Lázaro Martínez, Madrid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04633642/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04633642"
7,"NCT04780919","Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy",,"Completed","Has Results","Achilles Tendinopathy","Device: BTL-6000 FSWT|Device: BTL-6000 FSWT with sham applicator","Change in Cross-sectional Area at the Place of Maximum Tendon Width|Change in Maximum Pain in the Achilles Tendon Area|Change in Maximum Pain in the Achilles Tendon Area (Follow up)|Change of Ankle Dorsiflexion Range of Motion|Number of Participants With Hypoechogenic Areas|Number of Participants With Increased Thickness of Achilles Tendon|Change in VISA-A Questionnaire Score|Change in Single Leg Heel Rise Test|Change in Single Leg Hop Test","University Hospital, Motol","All","Child, Adult, Older Adult","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","EK- 1/21","February 1, 2021","April 2, 2021","April 2, 2021","March 4, 2021","June 2, 2021","June 28, 2021","University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czechia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04780919/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04780919"
8,"NCT02204124","Whipple Procedure: Standard of Care vs. Thunderbeat",,"Terminated","Has Results","Pancreatic Neoplasms|Bile Duct Carcinoma","Device: Thunderbeat|Device: Standard of care scissors, ligatures, clips, and sutures","Operative Blood Loss|Post-op Morbidity|Operative Time|Cost Using Thunderbeat Device|Anesthesia Time|Number of Participants Who Experienced Perioperative Complications|Number of Participants Who Experienced Postoperative Complications","Washington University School of Medicine","All","22 Years to 75 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","201311146","January 1, 2015","August 23, 2017","August 23, 2017","July 30, 2014","September 19, 2018","September 19, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02204124/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02204124"
9,"NCT02736825","Simulines Non-Inferiority Pivotal Study",,"Terminated","Has Results","Skin Laxity","Device: Ulthera System with standard transducer|Device: Ulthera System with prototype 2 simulines transducer","Number of Participants Who Achieved Greater Than or Equal to (>=) 20 mm^2 Reduction in Submental Area at Day 90|Number of Participants Who Achieved >=20 mm^2 Reduction in Submental Area at Day 180|Number of Participants Who Achieved >=20 mm^2 Reduction in Submental Area at Day 365|Number of Participants Who Showed Improvement in Overall Lifting and Tightening of Skin at Day 90|Number of Participants Who Showed Improvement in Overall Lifting and Tightening of Skin at Day 180|Number of Participants Who Showed Improvement in Overall Lifting and Tightening of Skin at Day 365|Percent Change From Baseline in Volume as Assessed by Quantificare 3 D Imaging System at Day 90|Percent Change From Baseline in Volume as Assessed by Quantificare 3D Imaging System at Day 180|Percent Change From Baseline in Volume as Assessed by Quantificare 3D Imaging System at Day 365|Number of Participants With Some Level of Improvement and Satisfaction on Day 90|Mean Treatment Times|Mean Pain Scores to Assess Participant's Treatment Related Comfort Level Based on Numeric Rating Scale (NRS)|Number of Participants With Overall Aesthetic Improvement as Assessed by Subject Global Aesthetic Improvement Scale (SGAIS) at Day 90|Number of Participants With Overall Aesthetic Improvement as Assessed by SGAIS at Day 180|Number of Participants With Overall Aesthetic Improvement as Assessed by SGAIS at Day 365|Number of Participants With Overall Aesthetic Improvement as Assessed by Clinician Global Aesthetic Improvement Scale (CGAIS) at Day 90|Number of Participants With Overall Aesthetic Improvement as Assessed by CGAIS at Day 180|Number of Participants With Overall Aesthetic Improvement as Assessed by CGAIS at Day 365","Ulthera, Inc|Merz North America, Inc.","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ULT-146","April 11, 2016","January 20, 2017","April 25, 2017","April 13, 2016","February 19, 2020","February 19, 2020","Clinical Testing of Beverly Hills, Beverly Hills, California, United States|Roseville Facial Plastic Surgery, Roseville, California, United States|Laser and Skin Surgery Center, Sacramento, California, United States|Dermatology Cosmetic Laser Medical Associates of La Jolla, San Diego, California, United States|AboutSkin Dermatology, Greenwood Village, Colorado, United States|Maryland Laser Skin and Vein Dermatology, Cockeysville, Maryland, United States|Wilmington Dermatology Center, Wilmington, North Carolina, United States|Premier Clinical Research, Spokane, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02736825/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02736825"
10,"NCT02351271","Cataract Surgery: Femto LDV Z8 Versus Conventional","COMFORT","Completed","Has Results","Cataract","Device: Femto LDV Z8|Device: Manual capsulorhexis&lens fragmentation","Effective Phaco Time (EPT)|Ease of Phacoemulsification|Number of Participants With Complete Treatment Pattern","Ziemer Ophthalmic Systems AG","All","50 Years and older   (Adult, Older Adult)","Not Applicable","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FL5940-0996","February 2015","December 28, 2016","February 28, 2017","January 30, 2015","October 23, 2019","October 23, 2019",,,"https://ClinicalTrials.gov/show/NCT02351271"
11,"NCT03320096","Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis","ULT-218","Completed","Has Results","Axillary Hyperhidrosis","Device: Microfocused ultrasound with visualization","Number of Participants With Hyperhidrosis Disease Severity Scale (HDSS) Score Reduction at Day 30 Post Second Treatment|Number of Participants With HDSS Score Reduction at Day 90 Post Second Treatment|Number of Participants With Gravimetric Axillary Sweat Reduction by at Least 50 Percent (%) at Days 30 and 90 Post Second Treatment|Number of Participants Who Showed Improvement With the Starch Iodine Test at Days 30 and 90 Post Second Treatment","Ulthera, Inc|Merz North America, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M960001007|DRKS00011603","December 13, 2016","June 19, 2017","August 22, 2017","October 25, 2017","July 10, 2019","July 10, 2019","Rosenpark Research, Study Research Center; Merz Investigational Site #0490099, Darmstadt, Germany|Haut- & Laserzentrum, Merz Investigational Site #0490362, Potsdam, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03320096/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03320096"
12,"NCT03599349","Evaluation of the Ulthera® System and Efficacy Correlation to Morphological Differences",,"Completed","Has Results","Facial and Neck Skin Laxity","Device: Microfocused ultrasound w/ visualization","Determine if There is a Correlation Between D90 Quantitative Efficacy Results of the Eyebrow and Lower Face Region With Where the TCPs Produced During Ultherapy Treatment Make Contact With Anatomical Layers of the Skin and Underlying Tissues.|Comparison of CGAIS Ratings to Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation.|The Subject Will Complete a SGAIS Assessing Overall Aesthetic Improvement at Day 90 and 180 Post-treatment Which Will be Compared to Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation|Qualitative Assessment of Overall Aesthetic Improvement Will be Compared to the Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation|The Subject Will Complete a Patient Satisfaction Questionnaire at the 90 and 180 Day Follow-up Visits Which Will be Compared to Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation|The Depth of Frontal Region Tissue Layers Will be Compared to the Quantitative Measurements of Lift in the Eyebrow Region to Determine if There is or is Not a Correlation.|The Depth of the Temple Region Tissue Layers Will be Compared to the Quantitative Measurement of Lift the Eyebrow Region to Determine if There is or is Not a Correlation.|The Depth of Cheek Tissue Layers Will be Compared to the Quantitative Measurement of Lift in the Lower Face Regions to Determine if There is or is Not a Correlation.|The Depth of Submental Tissue Layers Will be Compared to the Quantitative Measurement of Lift in the Lower Face Regions to Determine if There is or is Not a Correlation","Ulthera, Inc|Merz North America, Inc.","All","30 Years to 55 Years   (Adult)","Not Applicable","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ULT-145","August 20, 2015","July 13, 2016","July 13, 2016","July 26, 2018","June 11, 2019","June 11, 2019","Clinical Testing of Beverly Hills, Beverly Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT03599349"
13,"NCT03479944","Clinical Evaluation of FLACS With Combination of LenSx® and Centurion®",,"Completed","Has Results","Cataract","Procedure: FLACS|Procedure: Manual conventional surgery|Device: CENTURION® Vision System|Device: LenSx®","Cumulative Dissipated Energy (CDE)|Percent Change of Corneal Endothelial Cell Density (ECD) at Visit 5 (150-210 Days After Surgery) From Pre-Operative Visit|Percentage of Average Torsional Amplitude","Alcon Research","All","20 Years and older   (Adult, Older Adult)","Not Applicable","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CTB258-P001","August 22, 2018","November 19, 2018","May 17, 2019","March 27, 2018","December 16, 2019","December 16, 2019","Alcon Investigative Site, Iizuka City, Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03479944/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03479944/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03479944"
14,"NCT02658851","Cold Plasma for the Reduction of Lymphoceles Following PLND",,"Completed","Has Results","Lymphoceles Following Pelvic Lymph Node Dissection","Device: J-Plasma","Number of Participants With Incidence of Lymphocele Formation","Apyx Medical|AdventHealth","Male","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","808076","June 2016","June 27, 2017","June 27, 2017","January 20, 2016","December 2, 2020","December 2, 2020","Florida Hospital Global Robotics Institute, Celebration, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02658851/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02658851"
15,"NCT00946881","Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer",,"Completed","Has Results","Prostate Cancer","Drug: WST 11 -mediated -VTP","Prostate Biopsy|Prostate Biopsies|Pharmacokinetic Parameters-Cmax|Percentage of Prostatic Necrosis at Day 7 as Observed on the 7-Day MRI|International Index of Erectile Functions (IIEF) Results|International Prostate Symptom Score (IPSS) Results|Pharmacokinetic Parameters-Tmax|Pharmacokinetic Parameters -T1/2","Steba Biotech S.A.","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLIN901 PCM202","July 2009","July 2012","August 2012","July 27, 2009","November 6, 2017","February 12, 2019","UCLA - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Midtown Urology & Midtown Urology Surgical Center, Atlanta, Georgia, United States|Washington University School of Medicine- Barnes-Jewish Hospital, Saint Louis, Missouri, United States|NYU Urology Associates, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00946881"
16,"NCT03507036","Radio Frequency Microneedling for Suprapatellar Skin",,"Completed","Has Results","Skin Laxity","Device: Profound system","Photographic Knee Laxity and Texture Evaluation|Epidermal Thickness|Dermal Thickness|Change in Blood Flow at 0.25mm|Transepidermal Water Loss|Skin Elasticity|Change in Skin Laxity|Histological Analysis- Collagen 1|Gene Expression- Collagen 1|Epidermal Density|Histological Analysis- Collagen 3|Histological Analysis- Elastin|Gene Expression- Collagen 3|Gene Expression- Elastin|Gene Expression- Interluekin 6","University of Texas Southwestern Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 082017-079","March 15, 2018","January 30, 2019","May 1, 2019","April 24, 2018","December 3, 2020","December 3, 2020","University of Texas Southwestern Medical Center, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03507036/Prot_004.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03507036/SAP_005.pdf","https://ClinicalTrials.gov/show/NCT03507036"
17,"NCT01285960","ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids",,"Completed","Has Results","Uterine Fibroids","Device: ExAblate Treatment UF V2","Percentage of Participants With Leg Pain or Lower Extremity Neuropathy Persisting or Occuring Greater Than 10 Days Following Treatment","InSightec","Female","18 Years to 64 Years   (Adult)","Not Applicable","108","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UF031","May 2012","April 2016","April 2016","January 28, 2011","February 19, 2019","March 6, 2019","University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University, Durham, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|University of Virginia Health System, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01285960"
18,"NCT00365989","MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication",,"Completed","Has Results","Uterine Leiomyoma|Uterine Fibroids","Device: ExAblate Enhanced Sonication","Number of Adverse Events","InSightec","Female","18 Years and older   (Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UF018","October 2006","August 2008","August 2008","August 18, 2006","February 5, 2019","February 5, 2019","University of California at San Diego, La Jolla, California, United States|Lahey Clinic, Burlington, Massachusetts, United States|KNI, Kalamazoo, Michigan, United States|Cornell Vascular, New York, New York, United States|Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00365989"
19,"NCT01222494","Healthy Bodies, Healthy Kids",,"Completed","Has Results","Child Mental Disorders|Obesity|Metabolic Syndrome","Behavioral: Behavioral Weight Loss|Behavioral: Diet and Exercise Education","DEXA-measured Adiposity|Proton Density Fat Fraction (PDFF)|Carotid Artery Intima Media Thickness (CIMT)","Washington University School of Medicine|National Institute of Mental Health (NIMH)","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","47","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-0425|K23MH092435","July 2011","March 2017","March 2017","October 18, 2010","October 15, 2018","October 15, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01222494/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01222494"
20,"NCT02369848","Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)",,"Completed","Has Results","Peripheral Arterial Disease","Device: Shockwave Lithoplasty System","Effectiveness Endpoint Defined as Number of Participants withTarget Lesion Patency by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis|Safety Endpoint Defined as Composite of New-onset Major Adverse Events (MAEs)|Safety Measured by Number of Participants With Freedom From Major Adverse Events (MAEs)|Secondary Endpoint of Acute Procedural Success Achieved in Number of Participants|Secondary Patency Measured by Number of Participants With Target Lesion Patency by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis.|Secondary Patency Measured by Number of Participants With Target Lesion Patency (Without Adjunctive PTA) by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis.|Clinical Success - Improvement of Ankle-Brachial Index (ABI) of the Target Limb.|Clinical Success - Improvement of Ankle-Brachial (ABI) of the Target Limb.|Clinical Success","Shockwave Medical, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TD 0232","June 2015","December 2015","December 2016","February 24, 2015","April 18, 2018","April 18, 2018","Universitätsklinikum LKH Graz, Graz, Austria|Hanusch Krankenhaus, Vienna, Austria|Medizinische Universitat Wien, Vienna, Austria|Universitäts-Herzzentrum Freiburg & Bad Krozingen, Bad Krozingen, Germany|University Leipzig Medical Centre, Leipzig, Germany|St. Franziskus Hospital, Munster, Germany|RoMed Klinikum Rosenheim, Rosenheim, Germany|Auckland City Hospital, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT02369848"
21,"NCT03023488","Effects of Flexible Ureteroscopy on Renal Blood Flow",,"Completed","Has Results","Circulatory; Change","Procedure: flexible ureteroscopy|Device: Doppler Ultrasound examination|Device: laser lithotripsy","Peak Systolic Velocities (PSV) Measurement by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by Demonstrating the Change Between the Pre-operative and Post-operative Parameters.|End Diastolic Velocities (EDV) Measurement by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by Demonstrating the Change Between the Pre-operative and Post-operative Parameters.|Resistive Index (RI) Calculation by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by Demonstrating the Change Between the Pre-operative and Post-operative Parameters.|Pulsatility Index (PI) Calculation by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by Demonstrating the Change Between the Pre-operative and Post-operative Parameters.|Technical Details - Size of Ureteral Access Sheath|Technical Details - Name of Flexible Ureteroscope|Duration of the Flexible Ureteroscopy Operation|Operative Characteristics - Irrigation Pressure|Operative Characteristics - Intraoperative Complications|Post-Operative Characteristics - Complications","Marmara University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MAR.UAD.002|09.2016.181","February 2016","October 2016","December 2016","January 18, 2017","May 18, 2017","July 6, 2018",,,"https://ClinicalTrials.gov/show/NCT03023488"
22,"NCT03430245","VelaShape III & UltraShape Power for Thigh Circumference Reduction",,"Completed","Has Results","Circumference Reduction","Device: VelaShape III|Device: UltraShape Power","Circumference Change in the Thighs at the 12-week Follow-up Compared to Baseline Measurements|Change in the Thighs Circumference at Each Treatment Visit Post Baseline and at The 4 and 8 Week Follow-up Visits|Investigator Satisfaction|Subject Satisfaction","Syneron Medical","All","18 Years to 60 Years   (Adult)","Not Applicable","16","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DHF24451","February 19, 2018","May 30, 2019","July 3, 2019","February 12, 2018","December 26, 2019","January 9, 2020","Skin Laser & Surgery Specialist of NY/NJ, Hackensack, New Jersey, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03430245/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03430245"
23,"NCT00540969","Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases",,"Terminated","Has Results","Kidney Cancer|Melanoma (Skin)|Metastatic Cancer|Pain|Unspecified Adult Solid Tumor, Protocol Specific","Procedure: cryosurgery|Radiation: radiation therapy","Comparison of Pre- and Post-treatment Worst Pain in 24 Hours at Week 6 as Measured on the Numeric 0 to 10 Brief Pain Inventory (BPI) Scale|Average Difference in Pre- and Post-treatment Average Pain, Pain Relief, and Pain Interference Scores at Week 6 as Measured With the BPI|Average Difference in Pre- and Post-treatment Physical (PCS-8) and Mental (MCS-8) Quality of Life at Week 6 as Measured by the 2 Subscales of the Short Form (SF)-8","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","3","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCTG-N06C6|NCI-2009-00690|CDR0000570788","February 2008","January 2010","January 2010","October 8, 2007","February 1, 2017","November 21, 2018","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00540969"
24,"NCT00894738","Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures",,"Completed","Has Results","Mental Disorders","Procedure: Testing (MRS, US, DEXA, blood tests)","Carotid Artery Intima-media Thickness Measured by Ultrasonography.|Intrahepatic Triglyceride Content (IHTG) Measure by Liver Magnetic Resonance Spectroscopy.","Washington University School of Medicine","All","6 Years to 18 Years   (Child, Adult)",,"44","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","56790","January 1, 2010","March 31, 2016","June 1, 2016","May 7, 2009","June 6, 2019","June 6, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00894738"
25,"NCT02441036","Gene Expression Following Ultherapy® Treatment",,"Terminated","Has Results","Skin Laxity","Device: Ultherapy Treatment","Changes in Gene Expression in Facial Skin Tissue Treated With Ultherapy Compared to Control (Untreated) Tissue Through Microarray Profiling|Changes in Gene Expression of Apoptotic Genes Induced in Tissues Treated With Ultherapy Relative to Control (Untreated) Tissues by PCR Array|Changes in Gene Expression of Heat Shock Proteins Genes Induced in Tissues Treated With Ultherapy Relative to Control (Untreated) Tissues by PCR Array|Changes in Protein Expression in Tissues Treated With Ultherapy Compared to Control (Untreated) Tissue by Immunohistochemistry","Ulthera, Inc|Merz North America, Inc.","All","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","ULT-140","May 1, 2015","August 18, 2016","August 18, 2016","May 12, 2015","February 20, 2019","February 20, 2019","North Valley Plastic Surgery, Phoenix, Arizona, United States|Campbell Facial Plastic Surgery, Mequon, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02441036"
26,"NCT02667912","Distal Renal Denervation",,"Completed","Has Results","Hypertension, Resistant to Conventional Therapy","Procedure: Distal renal denervation|Procedure: Conventional renal denervation","Changes of 24h-mean Systolic BP Assessed by Ambulatory Blood Pressure Monitoring (ABPM)|Number of Adverse Events|Changes of Arterial Resistance Index Measured by Doppler Flowmetry in the Right Segmental Renal Arteries|Changes of Arterial Resistance Index Measured by Doppler Flowmetry in the Left Segmental Renal Arteries|Changes of Serum Creatinine|Changes of Estimated Glomerular Filtration Rate (eGFR)|Changes of 24h-mean Diastolic BP|Changes of 24h-mean Systolic BP|Changes of Office Systolic BP|Changes of Office Diastolic BP|Changes of Daytime Systolic BP|Changes of Daytime Mean Systolic BP|Changes of Daytime Mean Diastolic BP|Changes of Nighttime Mean Systolic BP|Changes of Nighttime Mean Diastolic BP","Federal State Budgetary Scientific Institution, Research Institute of Cardiology|Tomsk National Research Medical Center of the Russian Academy of Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","022","January 2013","July 2016","December 2016","January 29, 2016","February 1, 2019","December 24, 2020","Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02667912"
27,"NCT02667457","99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis",,"Terminated","Has Results","Carotid Artery Plaque","Radiation: 99mTc-rhAnnexin V-128","Number of Participants Evaluated for Imaging Feasibility|Percentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)|Left Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)|Right Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)|Ascending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)|Descending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)|Aortic Arch Uptake Correlation Imaging Assessment as Measured by Target to Background Ratio (TBR)|Left Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/Echogenicity|Right Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/Echogenicity|Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and Death|Number of Participants With Clinically Significant Abnormal Laboratory Values","Advanced Accelerator Applications","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAA-Annexin-04|CAAA113A32201","June 23, 2016","November 12, 2018","November 19, 2018","January 29, 2016","October 9, 2020","October 9, 2020","University of Ottawa Heart Institute, Ottawa, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02667457/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02667457/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02667457"
28,"NCT03789175","Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome",,"Completed","Has Results","Cancer|Skin Fibroblasts|Muscle Weakness","Dietary Supplement: Nicotinamide Riboside (NR)","Change in PCr Recovery Tc Measurement From Baseline to 12 Week NR Supplementation Using the 31P-MRS Skeletal Muscle Submaximal Exercise.|Change in Time of CPET Time as a Measure of Exercise Tolerance From Baseline to 12 Weeks of NR Supplementation.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","1","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","190034|19-H-0034","March 25, 2019","November 1, 2019","November 1, 2019","December 28, 2018","December 8, 2020","December 8, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03789175/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03789175"
29,"NCT02629094","Cardiometabolic Effects of Eplerenone in HIV Infection",,"Terminated","Has Results","Cardiac Steatosis|Hepatic Steatosis","Drug: Inspra /Eplerenone","Improvement of Cardiac Steatosis: Mean Change in Intraventricular Septum Percentage of Lipid by MR Spectroscopy.|Improvement of Hepatic Steatosis: Mean Change in Hepatic Percentage of Lipid by MR Spectroscopy","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","5","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160030|16-I-0030","December 2, 2015","September 11, 2017","September 11, 2017","December 14, 2015","July 17, 2018","July 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02629094/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02629094"
30,"NCT00084552","Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer",,"Completed","Has Results","Prostate Cancer|Sexual Dysfunction|Sexuality and Reproductive Issues","Radiation: radiation therapy","Erectile Dysfunction Rates|Percentage of Patients With Freedom From Biochemical Failure|Acute GI Toxicity|Acute GU Toxicity","Fox Chase Cancer Center","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","03-028|CDR0000365458","December 11, 2003","August 24, 2013","May 5, 2016","June 11, 2004","February 25, 2021","February 25, 2021","Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00084552"
31,"NCT02215369","SeCure Endovenous Laser Treatment Study","SeCure","Completed","Has Results","Chronic Venous Insufficiency","Device: VenaCure EVLT 400 µm fiber Procedure Kit","Acute Primary Ablation Success|Technical Success","Angiodynamics, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","112","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PV-VC300","January 2015","March 2018","January 14, 2019","August 13, 2014","April 21, 2020","May 19, 2020","Midwest Institute for Minimally Invasive Therapies, Melrose Park, Illinois, United States|Vein Clinics of America, Orland Park, Illinois, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|NYU Langone Medical Center, New York, New York, United States|UPMC, Pittsburgh, Pennsylvania, United States|The Vein Center of Virginia, Norfolk, Virginia, United States|Lake Washington Vascular, Bellevue, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02215369/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02215369/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02215369"
32,"NCT03708562","everlinQ Endovascular Access Systems Enhancements (EASE-2) Study",,"Completed","Has Results","Chronic Kidney Diseases","Device: everlinQ endoAVF System","Number of Participants With Procedural Success|Adverse Event Rate|Percentage of Participants With Primary Patency at 6 Months Post Index Procedure|Number of Participants With EndoAVF Maturation at 1, 3, and 6 Months Post Index Procedure|Time to Cannulation (Months)|Number of Participants With Cannulation Success at Defined Follow-up Intervals|Percentage of Participants With Assisted Primary Patency at 6 Months|Percentage of Participants With Secondary Patency at 6 Months Post Index Procedure|Percentage of Participants With Functional Patency of the endoAVF at 6 Months Post Index Procedure|Number of Participants With EndoAVF Related Reintervention|Percentage of Participants With Modified Primary Patency at 6 Months Post Index Procedure","TVA Medical Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD-0038","October 16, 2017","December 12, 2018","December 12, 2018","October 17, 2018","January 2, 2020","January 2, 2020","Sanatorio Italiano, Asunción, Paraguay","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03708562/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03708562"
33,"NCT02974140","Cataract Refractive Suite Study",,"Terminated","Has Results","Cataracts","Device: Cataract Refractive Suite (CRS)|Procedure: Standard manual technique","Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) Within 0.5 Diopter (D) of Predicted Postoperative Spherical Equivalent at Month 1|Cumulative Dissipated Energy (CDE)|Estimated Aspiration Fluid Used During Surgery|Phaco Aspiration Time Spent During Surgery","Alcon, a Novartis Company|Alcon Research","All","22 Years and older   (Adult, Older Adult)","Not Applicable","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CTK246-P001","March 2, 2017","July 25, 2017","July 25, 2017","November 28, 2016","September 14, 2018","September 14, 2018","Alcon Investigative Site, Panama City, Florida, United States|Alcon Investigative Site, Stillwater, Minnesota, United States|Alcon Investigative Site, Hurst, Texas, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02974140/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02974140/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02974140"
34,"NCT01807585","VenaSeal Sapheon Closure System Pivotal Study (VeClose)","VeClose","Completed","Has Results","Great Saphenous Vein (GSV) With Venous Reflux Disease","Device: VenaSeal SCS|Device: ClosureFast Radiofrequency Ablation (RFA)|Device: Roll-in (VenaSeal SCS)","Number of Participants With Complete Closure of the Target Vein at 3 Months|Intraoperative Pain|Ecchymosis at Day 3","Medtronic Endovascular|Sapheon, Inc.","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP-11101-01","March 2013","December 2013","April 10, 2017","March 8, 2013","June 26, 2018","June 26, 2018","Morrison Vein Institute, Scottsdale, Arizona, United States|GBK Cosmetic Laser Dermatology, San Diego, California, United States|Radiology Imaging Associates (RIA), Greenwood Village, Colorado, United States|Vein Clinics of America, Oakbrook Terrace, Illinois, United States|Prairie Education & Research Cooperative, Springfield, Illinois, United States|MD Laser Skin & Vein Institute, Hunt Valley, Maryland, United States|Vein Institute of Buffalo, North Tonawanda, New York, United States|Inovia Vein Specialty Center, Bend, Oregon, United States|Sentara Vascular Specialist, Virginia Beach, Virginia, United States|Lake Washington Vascular, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01807585"
35,"NCT03632655","A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches",,"Terminated","Has Results","Prostate Cancer|Elevated PSA","Procedure: prostate biopsy","Gleason Grade|Patient-reported Pain, as Measured on a 0-10 Likert Scale|Patient-reported Symptoms, as Measured by International Prostate Symptom Scores (IPSS) Questionnaire|Patient-reported Erectile Function, as Measured by International Index of Erectile Function (IIEF-5) Questionnaire|Patient-reported Quality of Life, as Measured by EPIC-CP Questionnaire|Adverse Events","Weill Medical College of Cornell University","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1705018187","December 23, 2017","October 8, 2020","October 8, 2020","August 15, 2018","July 13, 2021","July 13, 2021","Weill Cornell Medicine, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03632655/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03632655"
36,"NCT03194646","Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids","ASTEROID 6","Active, not recruiting","Has Results","Leiomyoma","Drug: Vilaprisan (BAY1002670)|Other: Standard of care","Percentage Change in Bone Mineral Density (BMD) of Lumbar Spine|Number of Bleeding Days|Endometrial Histology|Endometrial Thickness|Percentage Change From Baseline in BMD Measured at Lumbar Spine (Other Time Points Not Mentioned as Primary Safety Variable) and Hip/Femoral Neck","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1272","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16953|2016-004822-41","June 30, 2017","May 10, 2019","August 31, 2021","June 21, 2017","August 26, 2021","September 5, 2021","Central Research Associates, Inc., Birmingham, Alabama, United States|Women's Health Alliance of Mobile, Mobile, Alabama, United States|Coastal Clinical Research, Inc, Mobile, Alabama, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Diagnamics, Inc., Encinitas, California, United States|Grossmont Center for Clinical Research, La Mesa, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Womens Health Care Research Corporation, San Diego, California, United States|West Coast OB/GYN Associates, San Diego, California, United States|Advanced Women's Health Institute, Greenwood Village, Colorado, United States|Physicians Research Options, LLC, Lakewood, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Stamford Hospital, Stamford, Connecticut, United States|Office of Dr. James A. Simon, MD, Washington, District of Columbia, United States|Helix Biomedics, LLC, Boynton Beach, Florida, United States|Women's Medical Research Group, LLC, Clearwater, Florida, United States|Dr. Victoria Garcia & Associates, LLC Doral Medical Research, Doral, Florida, United States|M & O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Axcess Medical Research, LLC, Loxahatchee Groves, Florida, United States|Suncoast Clinical Research Center, Inc., New Port Richey, Florida, United States|Suncoast Clinical Research, Palm Harbor, Florida, United States|ONCOVA Clinical Research, Inc., Saint Cloud, Florida, United States|Physician Care Clinical Research, Sarasota, Florida, United States|Agile Clinical Research Trials, LLC, Atlanta, Georgia, United States|Atlanta Women's Research Institute, Inc., Atlanta, Georgia, United States|Medisense Inc at Atlantic Station, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Paramount Research Solutions-College Park, College Park, Georgia, United States|Fellows Research Alliance, Savannah, Georgia, United States|Journey Medical Research, Snellville, Georgia, United States|Center For Women's Research, Palos Heights, Illinois, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Research Integrity, LLC, Owensboro, Kentucky, United States|Praetorian Pharmaceutical Research, LLC, Marrero, Louisiana, United States|Southern Clinical Research Associates LLC, Metairie, Louisiana, United States|Omni Fertility and Laser Institute, Shreveport, Louisiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Baltimore Suburban Health, LLC, Pikesville, Maryland, United States|Continental Clinical Solutions, LLC, Towson, Maryland, United States|Wayne State University Physicians Group, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Women's Clinic of Lincoln, PC, Lincoln, Nebraska, United States|Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Lawrence OB/GYN Associates, Lawrenceville, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Bosque Womens Care, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Manhattan Medical Research, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Richmond ObGyn Associates PC, Staten Island, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Carolina Women's Research & Wellness Center, Durham, North Carolina, United States|Unified Women's Clinical Research, Greensboro, North Carolina, United States|Unified Women's Clinical Research - Morehead City, Morehead City, North Carolina, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Women's Health Alliance, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|Valaoras & Lewis OB/GYN, Winston-Salem, North Carolina, United States|Clinical Inquest Center, Ltd., Beavercreek, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vista Clinical Research, Columbia, South Carolina, United States|VitaLink Research - Greenville, Greenville, South Carolina, United States|Venus Gynecology, LLC former Magnolia OB/GYN Research Center, Myrtle Beach, South Carolina, United States|Invocare Clinical Research Center, LLC, West Columbia, South Carolina, United States|ClinSearch, LLC, Chattanooga, Tennessee, United States|Women's Physician Group, Memphis, Tennessee, United States|Discovery Clinical Trials, Dallas, Texas, United States|Signature GYN Services, Pllc, Fort Worth, Texas, United States|Office of Dr. Delbert Alan Johns, MD, Fort Worth, Texas, United States|Willowbend Health & Wellness Associates, Frisco, Texas, United States|Advances in Health, Inc., Houston, Texas, United States|The Woman's Hospital of Texas, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|MacArthur OB/GYN Mangement, LLC, Irving, Texas, United States|Family Medicine Clinic, Lampasas, Texas, United States|Seven Oaks Women's Center, San Antonio, Texas, United States|OB-GYN Physicians, Inc., Franklin, Virginia, United States|Tidewater Physicians for Women, Norfolk, Virginia, United States|Virginia Physicians For Women, North Chesterfield, Virginia, United States|Clinical Trials of Viriginia, Richmond, Virginia, United States|Synexus Research, LLC, Richmond, Virginia, United States|MultiCare Health Systems Women's Health Care, Covington, Washington, United States|900th Hospital of Joint Logistics Support Force, Fuzhou, Fujian, China|Sun Yat-Sen Memorial Hosp. Sun Yat-Sen Univ., Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|The 2nd Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Center for Reproductive Medicine,Tongji Medical college,HUST, Wuhan, Hubei, China|Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu, China|NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First Hospital of Jilin University, Changchun, Jilin, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|Shandong Provincial Hospital, Jinan, Shandong, China|The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Second University Hospital, Chengdu, Sichuan, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China|The Second Affliated Hospital of Wenzhou Medicial University, Wenzhou, Zhejiang, China|Beijing Hospital of Traditional Chinese Medicine, Beijing, China|Beijing Obstetrics and Gynecology Hospital,Capital Med.Uni., Beijing, China|Beijing Tiantan Hospital, Captial Medical University, Beijing, China|Peking Union Medical College Hospital CAMS, Beijing, China|Peking University First Hospital, Beijing, China|International Peace Maternity&Child Health Hospital of CWI, Shanghai, China|Changhai Hospital of Second Military Medical University, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|First Teaching Hosptial of Tianjin University of TCM, Tianjin, China|Tianjin Central Hospital of Gynecology obstetrics, Tianjin, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|MUDr. Radek Fiker s.r.o., Jihlava, Czechia|G-Centrum Olomouc s.r.o. Dr. Skrivanek, Olomouc, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|Centrum gynekologicke rehabilitace, Pisek, Czechia|Dr. Smrhova-Kovacs, Tabor, Czechia|Gynekologie MUDr. Pavlina Nejedla s.r.o., Vodnany, Czechia|Mehiläinen Kuopio, Kuopio, Finland|Lääkärikeskus Gyneko, Oulu, Finland|Queen Mary Hospital, Hongkong, Hong Kong|Kano's Clinic for Women, Nagoya, Aichi, Japan|Kyoritsu Narashinodai Hospital, Funabashi, Chiba, Japan|Juno Vesta Clinic Hatta, Matsudo, Chiba, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Jusendo Geneal Hospital Yuasa Foundation, Koriyama, Fukushima, Japan|Sato Hospital, Takasaki, Gunma, Japan|Primo Women's Clinic, Ebetsu, Hokkaido, Japan|Sapporo Maternity Women's Hospital, Sapporo, Hokkaido, Japan|Sapporo Shiroishi Obstetrics and Gynecology Hospital, Sapporo, Hokkaido, Japan|Hashimoto Clinic, Sapporo, Hokkaido, Japan|Ena Odori Clinic, Sapporo, Hokkaido, Japan|Sapporo Maternity Women's Minami1jo Clinic, Sapporo, Hokkaido, Japan|SAPPORO MEDICAL CENTER, NTT East Corporation, Sapporo, Hokkaido, Japan|Sapporo West Ladies Clinic, Sapporo, Hokkaido, Japan|Yoshio Clinic, Sapporo, Hokkaido, Japan|Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan|Asahi clinic, Takamatsu, Kagawa, Japan|Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan|Second Kawasaki Saiwai Clinic, Kawasaki, Kanagawa, Japan|Kurashiki Medical Clinic, Kurashiki, Okayama, Japan|Suita Municipal Hospital, Suita, Osaka, Japan|Medical Topia Soka Hospital, Soka, Saitama, Japan|Fuyo Association Seirei Numazu Hospital, Numazu, Shizuoka, Japan|Sei Womens Clinic, Bunkyo, Tokyo, Japan|Ginza Yoshida Clinic, Chuo-ku, Tokyo, Japan|Women's wellness Tsushima Ruriko josei life clinic Ginza, Chuo-ku, Tokyo, Japan|St.Luke's International Hospital, Chuoku, Tokyo, Japan|Akazawa Clinic, Fuchu, Tokyo, Japan|Medical Corp. Seikoukai New Medical Research System Clinic, Hachioji, Tokyo, Japan|Yokokura Clinic, Minato-ku, Tokyo, Japan|Toranomon Womens Clinic, Minato, Tokyo, Japan|Akasakamitsuke Miyazaki Obstetrics and Gynecology Clinic, Minato, Tokyo, Japan|Shirokane Ladies' Clinic, Minato, Tokyo, Japan|Kugayama Hospital, Setagaya-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan|Kato Internal medicine and Gynecology Clinic, Fukui, Japan|Sano Wemen's Clinic, Fukuoka, Japan|Unoki Clinic, Kagoshima, Japan|Medical corporation keizukai Chayamachi Ladies Clinic, Osaka, Japan|Chayamachi ladies Clinic Hommachi, Osaka, Japan|Medical Corporation Koshinkai Nomura Clinic Namba, Osaka, Japan|Izuma Clinic, Osaka, Japan|Shizuoka Saiseikai General Hospital, Shizuoka, Japan|Shizuoka City Shimizu Hospital, Shizuoka, Japan|Hospital Universitario ""José Eleuterio González"", Monterrey, Nuevo Leon, Mexico|Centro Integral Médico de San Juan del Río S. C., San Juan del Río, Querétaro, Mexico|Sanatorio Alcocer Pozo S. A. de C. V., Querétaro, Mexico|Kirkeparken Spesialistpraksis, Fredrikstad, Norway|Nesttun Spesialistpraksis AS, Nesttun, Norway|Medicus AS, Trondheim, Norway|Prywatna Klinika Ginekologiczno-Poloznicza, Bialystok, Poland|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|Vita Longa Sp. z o.o., Katowice, Poland|Gyncentrum Sp. z o.o., Katowice, Poland|Prywatny Gabinet Lekarski Ginekologia, Poloznictwo i Ultr., Lodz, Poland|Centrum Medyczne Chodzki, Lublin, Poland|Specjalistyczny Gabinet Ginekologiczno-Polozniczy, Lublin, Poland|Scientific Center of family health & human reprod. problems, Irkutsk, Russian Federation|Regional Clinical Hospital #2, Krasnodar, Russian Federation|Krasnoyarsk regional perinatal center, Krasnoyarsk, Russian Federation|City Clinical Hospital #13, Moscow, Russian Federation|Endocrinology Scientific Centre, Moscow, Russian Federation|Close Joint Stock Company ""Medical Company IDK"", Samara, Russian Federation|St. Petersburg Medical University n.a. I.P. Pavlov, St. Petersburg, Russian Federation|""Granti-Med"", St. Petersburg, Russian Federation|Scien. Res. Institute of Obsterics, Gyn. & Reproduction, St. Petersburg, Russian Federation|Dr L Reynders Practice, Lyttelton Manor, Gauteng, South Africa|University of Pretoria, Clinical Research Unit, Pretoria, Gauteng, South Africa|Femway Inc, Umhlanga, Kwazulu-Natal, South Africa|Durban International Clinical Research Site, Wentworth, Kwazulu-Natal, South Africa|Drs AEVITAS Clinic (Pty) Ltd, Cape Town, Western Cape, South Africa|University of Cape Town Clinical Research Centre, Cape Town, Western Cape, South Africa|Clintrials Centre for Clinical Research, Panorama, Western Cape, South Africa|Chulalongkorn Hospital, Bangkok, Thailand|Siriraj Hospital, Mahidol, Bangkok, Thailand|Cukurova Universitesi Tip Fakultesi Hastanesi, Adana, Turkey|Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Etlik Zubeyde Hanim Kadin Hastaliklari Egitim Arastirma Hast, Ankara, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi Cerrahpasa-Cerrahpasa Tip Fakultesi, Istanbul, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03194646/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03194646/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03194646"
